Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific

National Institutes of Health (NIH) logo

National Institutes of Health (NIH)

Status

Unknown

Conditions

HIV Infections
HIV Related Neurological Diseases

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT00168246
77/05

Details and patient eligibility

About

This study will determine the prevalence of HIV-related neurological disorders in the countries of the Asia-Pacific Region.

Full description

This a cross-sectional study to determine the prevalence of HIV-related Neurological Disorders in the countries of the Asia-Pacific Region. Researchers will visit each country site for a period of 2-3 weeks and work with local investigators. Outpatients will be evaluated once-only for the presence of HIV-related symptomatic peripheral neuropathy and HIV-related Neurocognitive Impairment. Inpatients at the sites will be evaluated once-only for the presence of HIV dementia, cerebral toxoplasmosis, cerebral tuberculosis, cryptococcal meningitis, lymphoma, PML and CMV encephalitis. The Primary outcomes are: To determine the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites To determine the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites To determine the prevalence of central nervous system opportunistic infections and tumours at the APNAC-10 sites The secondary outcomes are: To determine the degree of cognitive impairment in patients presenting with HIV-related cognitive impairment at the APNAC-10 sites To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior AIDS defining illnesses (ADIs) of patients presenting with HIV-related neurocognitive impairment and ADC at the APNAC-10 sites To compare the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries To compare the prevalence of HIV-related neurocognitive impairment and ADC between the APNAC-10 sites To describe the severity of symptoms of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior ADIs of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites To determine what proportion of symptomatic peripheral sensory neuropathy may be ascribed to HIV alone, to the use of nucleoside analogues To compare the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries To compare the prevalence of symptomatic peripheral sensory neuropathy between the APNAC-10 sites To determine the prevalence of asymptomatic peripheral neuropathy To describe the presenting symptoms and signs of patients presenting with CNS OIs and tumours at the APNAC-10 sites To describe the neuroradiological findings of patients presenting with CNS OIs and tumours at the APNAC-10 sites To determine the serological, culture and other diagnostic test results of patients presenting with CNS OIs and tumours at the APNAC-10 sites To determine the CD4 cell counts, HIV viral loads and prior ADIs of patients presenting with CNS OIs and tumours at the APNAC-10 sites To compare the prevalence of CNS OIs and tumours at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries To compare the prevalence of CNS OIs and tumours between the APNAC-10 sites

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Patients are HIV infected
  • Patients are eighteen years or older

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems